PICO Negative Pressure for Uninfected Foot Ulcers and Wound Dehiscence (BALPIC)
BALPIC
PICO Negative Pressure for the Treatment of Uninfected Foot Ulcers and Wound Dehiscence - an Unblinded, Randomized-controlled, Superiority Trial (BALPIC Trial)
1 other identifier
interventional
300
1 country
1
Brief Summary
The investigators compare negative pressure wound therapy (NPWT) using the PICO 7 system versus professional wound debridement alone in adult orthopedic patients with acute, non-infected wound dehiscence or diabetic foot ulcers. Patients are randomized 1:1 to either PICO therapy (minimum 7 days, up to 42 days) or standard wound care (professional debridement without NPWT). The primary outcome is wound closure without surgical revision at Day 42. The trial is stratified for diabetic foot ulcers to enable subgroup analysis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2026
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 29, 2026
CompletedStudy Start
First participant enrolled
January 29, 2026
CompletedFirst Posted
Study publicly available on registry
February 10, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 30, 2028
February 10, 2026
February 1, 2026
1.9 years
January 29, 2026
February 6, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Wound closure without surgical revision at Day 42
Wound closure is defined as reduction of wound size by a minimum of 90% compared to baseline, without need for surgical revision. Wound failure is defined as persistent wound (less than 90% reduction) after 42 days or surgical wound revision during the study period.
Day 42 (±7 days)
Secondary Outcomes (6)
2. Rapidity of wound closure
Day 7, 14, 21, 28, 35, and 42
Wound closure without surgical revision at Day 7, 14, 21, 28, and 35
Day 7, 14, 21, 28, and 35 (±2 days)
4. Wound closure for diabetic foot ulcers only (stratified analysis)
Day 42 (±7 days)
5. Adverse events related to wound therapy
Day 1 to Day 42 (±7 days)
6. Length of hospital stay
Day 1 to Day 42 (±7 days)
- +1 more secondary outcomes
Study Arms (2)
PICO
EXPERIMENTALApplication of PICO 7 Single Use NPWT System at -80 mmHg for a minimum of 7 days. PICO therapy may be continued for up to 42 days based on clinical necessity. Device change every 7 days. Wound assessment weekly. SMITH \& NEPHEW MEDICAL LTD. PICO 7 15CM X 20CM; NEGATIVE PRESSURE WOUND THERAPY POWERED SUCTION PUMP (UDI 04582111156419). The PICO system creates a closed environment over the wound, evacuating exudate into an absorptive dressing while promoting wound closure through controlled suction.
Professional Wound CAre
OTHERProfessional wound debridement by specialized wound nurses, including dressing changes and local antiseptics if clinically indicated, without the use of any negative pressure device. Treatment for up to 42 days based on clinical necessity. Wound assessment weekly. Individualized professional wound care according to hospital and Swiss nursing guidelines. The intensity of debridement, dressing type, and antiseptic use lies at the discretion of the wound nurse and will be recorded.
Interventions
Professional wound debridement by specialized wound nurses, including dressing changes and local antiseptics if clinically indicated, without the use of any negative pressure device. Treatment for up to 42 days based on clinical necessity. Wound assessment weekly. Individualized professional wound care according to hospital and Swiss nursing guidelines. The intensity of debridement, dressing type, and antiseptic use lies at the discretion of the wound nurse and will be recorded.
Eligibility Criteria
You may qualify if:
- \- Age ≥ 18 years
- Able to consent
- Patient of orthopaedic surgery or of the (Diabetic) Foot Polyclinic at the Balgrist University Hospital
- Presence of an acute, dehiscent, clinically uninfected wound requiring additional measures
- First episode of wound treatment for the actual wound (no recurrences) in the last 12 months
- Wound measuring ≥ 0.5 cm in wide, length or depth
- days of scheduled follow-up
- Bacterial orthopaedic infections of any nature, independently of implants or co-morbidities; according to clinical, laboratory, radiological, microbiological features of infection
- First or second episode of infection
You may not qualify if:
- \- Patient's individual refusal to participate
- Patient already treated with any vacuum-assisted wound device for any wound in the last 12 months; independently of therapy success, the hospital or the localization of the prior wound
- Underlying liquor leak (spine surgery)
- Visually active bleeding from the wound
- Wound size \>10 cm in any dimension
- Anticipated active clinical follow-up of less than 42 days
- Other wound treatments besides PICO and debridement (e.g. hyperbaric oxygen therapy, other negative-pressure devices, local antibiotics, local antibiotic dressings) (however, local antiseptics and dressing changes remain allowed)
- Immediate surgical wound revision in the operating theatre for closure
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ilker Uckaylead
Study Sites (1)
Balgrist University Hospital
Zurich, 8008, Switzerland
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
Ilker Uçkay, Prof. Dr. med.
Balgrist University Hospital, University of Zurich, Zurich, Swizerland
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Prof. Dr. med. Ilker Uçkay
Study Record Dates
First Submitted
January 29, 2026
First Posted
February 10, 2026
Study Start
January 29, 2026
Primary Completion (Estimated)
December 31, 2027
Study Completion (Estimated)
June 30, 2028
Last Updated
February 10, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, ICF, CSR
- Time Frame
- After the final analysis
- Access Criteria
- Reasonable scientific request to the corresponding Sponsor-Investigator
The investigators may share anonymized key elements upon reasonable scientific request to the corresponding persons